Hepatitis Monthly

Published by: Kowsar

Risk Factors of HCV Seroconversion in Hemodialysis Patients in Tabriz, Iran

Mohammad Hossein Somi 1 , Jalal Etemadi 2 , Morteza Ghojazadeh 1 , Sara Farhang 3 , Mehrasa Faramarzi 1 , Sanaz Foroutan 1 and Maryam Soleimanpour 1 , *
Authors Information
1 Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Chronic Kidney Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Cliniclal Psychiatry Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
Article information
  • Hepatitis Monthly: June 01, 2014, 14 (6); e17417
  • Published Online: June 1, 2014
  • Article Type: Research Article
  • Received: January 6, 2014
  • Revised: March 16, 2014
  • Accepted: April 20, 2014
  • DOI: 10.5812/hepatmon.17417

To Cite: Somi M H, Etemadi J, Ghojazadeh M, Farhang S, Faramarzi M, et al. Risk Factors of HCV Seroconversion in Hemodialysis Patients in Tabriz, Iran, Hepat Mon. 2014 ; 14(6):e17417. doi: 10.5812/hepatmon.17417.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999; 6(1): 35-47[PubMed]
  • 2. Trinks J, Gadano A, Argibay P. Evolving trends in the hepatitis C virus molecular epidemiology studies: from the viral sequences to the human genome. Epidemiol Res Int. 2012; 2012: 10[DOI]
  • 3. Thomas DB, Mangan RL. Nontarget impact of spinosad GF-120 bait sprays for control of the Mexican fruit fly (Diptera: Tephritidae) in Texas citrus. J Econ Entomol. 2005; 98(6): 1950-6[PubMed]
  • 4. U. S. Public Health Service . . Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep. 2001; 50: 1-52[PubMed]
  • 5. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol. 2003; 36(1): 47-53[PubMed]
  • 6. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[DOI][PubMed]
  • 7. Seaworth BJ, Garrett LE, Stead WW, Hamilton JD. Non-A, non-B hepatitis and chronic dialysis--another dilemma. Am J Nephrol. 1984; 4(4): 235-9[PubMed]
  • 8. Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008; 28(4): 628-40[DOI][PubMed]
  • 9. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003; 8(5): 256-60[PubMed]
  • 10. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 11. Somi MH, Ardalan MR, Sokhanvar H, Farhang S, Pouri A. Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study. Arch Clin Infect Dis. 2007; 2(1)
  • 12. Dienstag JL, Stevens CE, Szmuness W. Non-A non-B Hepatitis.. 1981; : 119-37
  • 13. Somi MH, Keivani H, Ardalan MR, Farhang S, Pouri AA. Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran. Saudi J Kidney Dis Transpl. 2008; 19(3): 461-5[PubMed]
  • 14. Koirala SR, Singh RP, Malla RR, Khakurel S. Prevalence of Hepatts b, Hepatts c and HIV Infections among chronic Renal Failure Patents on Hemodialysis. Post-Graduate Med J NAMS. 2009; 9(2): 6-13
  • 15. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8): 556-62[DOI][PubMed]
  • 16. Fabrizi F, Raffaele L, Bacchini G, Guarnori I, Pontoriero G, Erba G, et al. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays. Nephrol Dial Transplant. 1993; 8(8): 744-7[PubMed]
  • 17. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 1992; 38(1): 44-8[PubMed]
  • 18. Sandhu J, Preiksaitis JK, Campbell PM, Carriere KC, Hessel PA. Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Am J Epidemiol. 1999; 150(1): 58-66[PubMed]
  • 19. Sampietro M, Badalamenti S, Salvadori S, Corbetta N, Graziani G, Como G, et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int. 1995; 47(3): 911-7[PubMed]
  • 20. Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaard N, Rasmussen LS, et al. Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int. 1993; 43(6): 1353-6[PubMed]
  • 21. Dentico P, Buongiorno R, Volpe A, Carlone A, Carbone M, Manno C, et al. Prevalence and incidence of hepatitis C virus (HCV) in hemodialysis patients: study of risk factors. Clin Nephrol. 1992; 38(1): 49-52[PubMed]
  • 22. van der Poel CL, Reesink HW, Schaasberg W, Leentvaar-Kuypers A, Bakker E, Exel-Oehlers PJ, et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet. 1990; 335(8689): 558-60[PubMed]
  • 23. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol. 1995; 90(5): 794-9[PubMed]
  • 24. Shaheen FA, Huraib SO, Al-Rashed R, Aldrees A, Arif M, Al Jeffry M, et al. Prevalence of hepatitis C antibodies among hemodialysis patients in the Western province of saudi arabia. Saudi J Kidney Dis Transpl. 1995; 6(2): 136-9[PubMed]
  • 25. Huraib S, al-Rashed R, Aldrees A, Aljefry M, Arif M, al-Faleh FA. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. Nephrol Dial Transplant. 1995; 10(4): 470-4[PubMed]
  • 26. Vitale C, Tricerri A, Marangella M, Vacha GM, Giorcelli G, Marini C, et al. Epidemiology of hepatitis C virus infection in dialysis units: first-versus second-generation assays. Nephron. 1993; 64(2): 315-6[PubMed]
  • 27. Ahmetagic S, Muminhodzic K, Cickusic E, Stojic V, Petrovic J, Tihic N. Hepatitis C infection in risk groups. Bosn J Basic Med Sci. 2006; 6(4): 13-7[PubMed]
  • 28. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002; 9(5): 390-2[PubMed]
  • 29. Al-Jamal M, Al-Qudah A, Al-Shishi KF, Al-Sarayreh A, Al-Quraan L. Hepatitis C virus (HCV) infection in hemodialysis patients in the south of Jordan. Saudi J Kidney Dis Transpl. 2009; 20(3): 488-92[PubMed]
  • 30. Pereira BJ. Hepatitis C in organ transplantation: its significance and influence on transplantation policies. Curr Opin Nephrol Hypertens. 1993; 2(6): 912-22[PubMed]
  • 31. Alavian SM. Re: posttransplant diabetes mellitus in kidney allograft recipients at Shaheed Hasheminejad Hospital. Iran J Kidney Dis. 2008; 2(2): 110-1[PubMed]
  • 32. Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B. Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocr Disord. 2004; 4(1): 4[DOI][PubMed]
  • 33. Saberi HR, Moravveji AR, Fakharian E, Kashani MM, Dehdashti AR. Prevalence of metabolic syndrome in bus and truck drivers in Kashan, Iran. Diabetol Metab Syndr. 2011; 3(1): 8[DOI][PubMed]
  • 34. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int. 1993; 44(6): 1322-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments